A study published online in the August 2014 edition of the Annals of Surgical Oncology shows that BluePrint (Agendia Inc) proves to be superior to conventional subtyping for analyzing breast cancer before surgery. 
The study, which will also be published in the October print edition of the journal, is part of the ongoing Neoadjuvant Breast Registry Symphony Trial (NBRST, pronounced "N-breast").
These finding may eventually change the way physicians evaluate and treat breast cancer. The researchers concluded that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional immunohistochemistry (IHC)-fluorescence in situ hybridization (FISH) pathology tests.
To read the full article, go to Onco'Zine - The International Oncology Network (http://adc.expert/1t2kjJU...